ClinicalTrials.gg
RecruitingNCT06445517Updated Jul 24, 2026

Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma

A Phase 1 interventional study of ISM8207 in Advanced Solid Tumors and Relapsed/Refractory B-cell Lymphoma, sponsored by InSilico Medicine Hong Kong Limited. Recruiting at 4 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by InSilico Medicine Hong Kong Limited · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 6 months later.
Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to study ISM8207 in participants with advanced solid tumors and relapsed/refractory B-cell lymphoma. The primary objective is to evaluate the safety and tolerability of ISM8207 orally administered in participants with advanced solid tumors and relapsed/refractory B-cell lymphoma

02

Conditions studied

  • Advanced Solid Tumors
  • Relapsed/Refractory B-cell Lymphoma

Browse trials for

Keywords

  • Advanced solid tumors
  • Relapsed/refractory B-cell lymphoma
  • Lymphoma, B-cell
03

In context

Lymphoma, B-Cell

885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

This study's planned enrollment of 60 is above the median of 34 across 773 interventional studies indexed under Lymphoma, B-Cell.

Browse Lymphoma, B-Cell studies →

Lead sponsor

InSilico Medicine Hong Kong Limited is the lead sponsor of 11 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants with age ≥18 years at the time of signing the .
  2. Advanced solid tumors: confirmed advanced or solid tumors who have disease progression after standard therapy, intolerable to standard therapy, or for whom no standard therapy exists.

    B-cell lymphoma: Histologically confirmed B-cell lymphoma who had received at least one prior line of standard therapy and were after or refractory to the standard therapy.

  3. Have measurable or evaluable lesions in Part 1 and at least one measurable target lesion in Part 2 as defined by (RECIST) criteria or Lugano 2014.
  4. PS (Eastern Cooperative Oncology Group Performance Status)≤1.
  5. of ≥12 weeks as judged by the investigator.
  6. Adequate organ function as determined by medical assessment.
  7. Capable of providing signed ICF and complying with the requirements and restrictions listed in the ICF and in this study protocol.
  8. Female subjects of and male subjects must agree to use an effective method of during the treatment period and for 90 days after the last dose of ISM8207.

Exclusion criteria

Exclusion Criteria:

  1. Prior treated with other QPCTL, 7 or SIRPα inhibitors.
  2. Burkitt lymphoma/leukemia, plasma cell myeloma, plasmablastic lymphoma.
  3. Participation in other therapeutic clinical studies within 28 days or 5 half- lives (whichever is shorter) prior to first dose of study treatment.
  4. Anti-tumor therapy (chemotherapy, immunotherapy, targeted therapy, biologic therapy, or other anti-tumor therapy) within 28 days or 5 half-lives, whichever is shorter prior to first dose of study treatment.
  5. Previous stem cell transplantation or autologous stem cell. transplantation within 3 months prior to first receiving study treatment.
  6. Unresolved toxicity of Grade >1 attributed to any prior therapies (excluding alopecia).
  7. Received antitumor therapy within 7 days prior to the first study treatment administration.
  8. A serious illness or medical condition(s)
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

RECIST

The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Dose Escalation: ISM8207

    Participants will receive ISM8207 orally once on day 1 during single dose period (3 days) then once daily in repeated 28-day cycles from Cycle 1 onwards.

    Drug: ISM8207

  • Experimental
    Dose Expansion: ISM8207

    Participants will receive ISM8207 orally once daily in repeated 28-day cycles.

    Drug: ISM8207

Interventions

  • DrugISM8207

    Pharmaceutical formulation: Capsules Mode of Administration: Oral

06

What researchers measure

Primary outcomes

  1. Incidence of dose-limiting toxicity (DLT) events

    Time frame: 31 days

  2. Incidence and severity of adverse events (AEs)

    Time frame: Approximately 2 years

  3. Recommended phase 2 dose (RP2D)

    Time frame: 31 days

Secondary outcomes

  1. objective response rate (ORR)

    Time frame: Approximately 2 years

  2. best objective response (BOR)

    Time frame: Approximately 2 years

  3. duration of response (DoR)

    Time frame: Approximately 2 years

  4. disease control rate (DCR)

    Time frame: Approximately 2 years

  5. progression-free survival (PFS)

    Time frame: Approximately 2 years

  6. 6-month overall survival (OS) rates

    Time frame: Approximately 2 years

  7. 1-year overall survival (OS) rates

    Time frame: Approximately 2 years

  8. maximum observed concentration (Cmax)

    Time frame: Approximately 2 years

  9. time of maximum observed concentration (Tmax)

    Time frame: Approximately 2 years

  10. area under the concentration-time curve (AUC)

    Time frame: Approximately 2 years

  11. terminal half-life (t1/2)

    Time frame: Approximately 2 years

  12. apparent clearance (CL/F)

    Time frame: Approximately 2 years

  13. apparent volume of distribution (Vz/F)

    Time frame: Approximately 2 years

  14. maximum observed concentration at steady state (Css,max)

    Time frame: Approximately 2 years

  15. minimum observed concentration at steady state (Css,min)

    Time frame: Approximately 2 years

  16. average concentration at steady state (Css,av)

    Time frame: Approximately 2 years

  17. time of Css,max (Tss,max)

    Time frame: Approximately 2 years

  18. AUC from time 0 to time dosing interval (AUCss,0-tau)

    Time frame: Approximately 2 years

  19. CLss/Fss

    Time frame: Approximately 2 years

  20. Vz/Fss

    Time frame: Approximately 2 years

  21. accumulation ratio of Cmax (RCmax) after multiple doses

    Time frame: Approximately 2 years

  22. accumulation ratio of AUC (RAUC) after multiple doses

    Time frame: Approximately 2 years

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Nov 2026, 31 months after the start.

Of 90 industry-sponsored phase 1 interventional studies under Lymphoma, B-Cell, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 81. This study's planned 31 months is below that.

Counting every sponsor, half of 207 studies reached it within 51 months; a quarter within 37 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2024
First posted
Jun 6, 2024
StartActual
Apr 25, 2024
Primary completionEst.
Nov 30, 2026
CompletionEst.
Feb 28, 2027
Last update
Jul 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06445517
Lead sponsor
InSilico Medicine Hong Kong Limited
Responsible party
Sponsor
First posted
Jun 6, 2024
Start date
Apr 25, 2024
Primary completion
Nov 30, 2026 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Jul 24, 2026

Study contacts

Yichen Liu
Contact
Insilico-Clinicaltrial@insilico.ai
021-50831718

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion